Lipocine Inc reports results for the quarter ended March 31 - Earnings Summary

• Lipocine Inc LPCN.OQ reported a quarterly adjusted loss of 35 cents​​ per share for the quarter ended March 31, lower than the same quarter last year, when the company reported EPS of 66 cents. The lone analyst forecast for the quarter was for a loss of 35 cents per share.

• Revenue rose 1,132.3% to $93.86 million from a year ago; analysts expected $352.00 thousand.

• Lipocine Inc's reported EPS for the quarter was a loss of 35 cents​.

• The company reported a quarterly loss of $1.87 million.

• Lipocine Inc shares had risen by 3.8% this quarter and lost 32.4% so far this year.

FORECAST CHANGES

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Lipocine Inc is $6.75

This summary was machine generated from LSEG data May 8 at 02:16 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)